Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Christopher J, Tichacek"'
Real-time, volumetric imaging of radiation dose delivery deep into the liver during cancer treatment
Autor:
Wei Zhang, Ibrahim Oraiqat, Dale Litzenberg, Kai-Wei Chang, Scott Hadley, Noora Ba Sunbul, Martha M. Matuszak, Christopher J. Tichacek, Eduardo G. Moros, Paul L. Carson, Kyle C. Cuneo, Xueding Wang, Issam El Naqa
Publikováno v:
Nature Biotechnology.
Ionizing radiation acoustic imaging (iRAI) allows online monitoring of radiation’s interactions with tissues during radiation therapy, providing real-time, adaptive feedback for cancer treatments. We describe an iRAI volumetric imaging system that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baeb86f86e18ecd0f1de387666f699af
https://doi.org/10.1038/s41587-022-01593-8
https://doi.org/10.1038/s41587-022-01593-8
Autor:
Narges K. Tafreshi, Haitao Ji, Robert W. Engelman, Jordan N Reff, Zhen Wang, Thaddeus J. Wadas, Alberto Chiappori, Christopher J. Tichacek, David L. Morse, Ghassan El-Haddad, Darpan N. Pandya, Mikalai M. Budzevich, David Boulware, Jonathan R. Strosberg
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:3408-3421
There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide 177Lu ([177Lu]Lu-DOTA-TATE)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c91d6f8d22fa2108b214d602152c043
https://doi.org/10.1007/s00259-021-05315-1
https://doi.org/10.1007/s00259-021-05315-1
Autor:
Christopher J. Tichacek, Mikalai M. Budzevich, Thaddeus J. Wadas, David L. Morse, Eduardo G. Moros
Publikováno v:
Molecules, Vol 24, Iss 18, p 3397 (2019)
Using targeted ligands to deliver alpha-emitting radionuclides directly to tumor cells has become a promising therapeutic strategy. To calculate the radiation dose to patients, activities of parent and daughter radionuclides must be measured. Scintil
Externí odkaz:
https://doaj.org/article/31793922f8a24839a3aadae3d2f00f8b
Autor:
Michael L. Langsen, Robert W. Engelman, Michael L. Doligalski, Darpan N. Pandya, Mark L. McLaughlin, Narges K. Tafreshi, David L. Morse, HyunJoo Kil, Christopher J. Tichacek, Eduardo G. Moros, Thaddeus J. Wadas, Kenneth L. Gage, John A. Vallas, David Boulware, Nella C. Delva, Mikalai M. Budzevich
Publikováno v:
ACS Pharmacol Transl Sci
[Image: see text] Lipophilicity is explored in the biodistribution (BD), pharmacokinetics (PK), radiation dosimetry (RD), and toxicity of an internally administered targeted alpha-particle therapy (TAT) under development for the treatment of metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c127ceea470c3ba7b4f9e79b33c0f87b
https://pubmed.ncbi.nlm.nih.gov/33860213
https://pubmed.ncbi.nlm.nih.gov/33860213
Autor:
Narges K, Tafreshi, Darpan N, Pandya, Christopher J, Tichacek, Mikalai M, Budzevich, Zhen, Wang, Jordan N, Reff, Robert W, Engelman, David C, Boulware, Alberto A, Chiappori, Jonathan R, Strosberg, Haitao, Ji, Thaddeus J, Wadas, Ghassan, El-Haddad, David L, Morse
Publikováno v:
European journal of nuclear medicine and molecular imaging. 48(11)
There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide[[These results suggest sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::677e887c74e02cd62addb2ebdfbd61cc
https://pubmed.ncbi.nlm.nih.gov/33772332
https://pubmed.ncbi.nlm.nih.gov/33772332
Autor:
Robert W. Engelman, David L. Morse, Mikalai M. Budzevich, HyunJoo Kil, Mark L. McLaughlin, Kenneth L Gage, Michael L. Doligalski, Eduardo G. Moros, Christopher J. Tichacek, Narges K. Tafreshi, Thaddeus J. Wadas, Ariosto S. Silva
Publikováno v:
Molecular pharmaceutics. 17(11)
Targeted α particle therapy (TAT) is ideal for treating disease while minimizing damage to surrounding nontargeted tissues due to short path length and high linear energy transfer (LET). We developed a TAT for metastatic uveal melanoma, targeting th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55eb5220ddf1fc9defae19528b1a506c
https://pubmed.ncbi.nlm.nih.gov/32960613
https://pubmed.ncbi.nlm.nih.gov/32960613
Autor:
Christopher J. Tichacek, Thaddeus J. Wadas, Mikalai M. Budzevich, Eduardo G. Moros, David L. Morse, Darpan N. Pandya, Mark L. McLaughlin, Michael L. Doligalski, Ghassan El-Haddad, Narges K. Tafreshi, Nikhil I. Khushalani
Publikováno v:
Molecules
Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7117ddc44624840692fe8fceb3e3cc25
https://pubmed.ncbi.nlm.nih.gov/31779154
https://pubmed.ncbi.nlm.nih.gov/31779154
Autor:
Mikalai M. Budzevich, David L. Morse, Thaddeus J. Wadas, Christopher J. Tichacek, Eduardo G. Moros
Publikováno v:
Molecules
Volume 24
Issue 18
Molecules, Vol 24, Iss 18, p 3397 (2019)
Volume 24
Issue 18
Molecules, Vol 24, Iss 18, p 3397 (2019)
Using targeted ligands to deliver alpha-emitting radionuclides directly to tumor cells has become a promising therapeutic strategy. To calculate the radiation dose to patients, activities of parent and daughter radionuclides must be measured. Scintil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b733dfed454f8642db872f1c3894fc
https://pubmed.ncbi.nlm.nih.gov/31546752
https://pubmed.ncbi.nlm.nih.gov/31546752
Autor:
Narges K. Tafreshi, Nancy D. Kock, Ghassan El-Haddad, Thaddeus J. Wadas, Jane L. Messina, Adam Weaver, Christopher J. Tichacek, Nikunj Bhatt, Michael L. Doligalski, Darpan N. Pandya, David L. Morse, HyunJoo Kil, David Boulware, Nikhil I. Khushalani, William R. Gibbons, Pierre L. Triozzi, Eduardo G. Moros, Epifanio Ruiz, Nella C. Delva, Mikalai M. Budzevich, Mark L. McLaughlin
New effective therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a median survival of less than 1 y. The melanocortin 1 receptor (MC1R) is expressed in 94% of uveal melanoma metastases, and a MC1R-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360fb3c67f26a8360b8de9500243ddfa
https://europepmc.org/articles/PMC6681690/
https://europepmc.org/articles/PMC6681690/
Autor:
HyunJoo Kil, David L. Morse, Nikunj Bhatt, Mikalai M. Budzevich, Nella C. Delva, Christopher J. Tichacek, Narges K. Tafreshi, Epifanio Ruiz, Mark L. McLaughlin, Michael L. Doligalski, Darpan N. Pandya, Thaddeus J. Wadas
Publikováno v:
Cancer Research. 77:5198-5198
New effective therapies are greatly needed for uveal melanoma, the most common ocular malignancy, which has a very poor prognosis with a median survival of less than one year when metastatic disease develops. The melanocortin 1 receptor (MC1R) is exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118c3ecd2eb44dc60f000a556d702a4e
https://doi.org/10.1158/1538-7445.am2017-5198
https://doi.org/10.1158/1538-7445.am2017-5198